Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Finding Study of NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibody, As a Single Agent, in Combination with Anti-PD-1 Antibody, and in Combination with Weekly Paclitaxel (Standard of Care) in Patients with Mesothelin Expressing Ovarian, Pancreatic, Non-Small-Cell-Lung and Triple-Negative Breast Cancers

NCT05403554 is registered in ClinicalTrials.gov with Light Chain Bioscience - Novimmune SA as lead sponsor.

NCT NCT05403554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05403554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Finding Study of NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibody, As a Single Agent, in Combination with Anti-PD-1 Antibody, and in Combination with Weekly Paclitaxel (Standard of Care) in Patients with Mesothelin Expressing Ovarian, Pancreatic, Non-Small-Cell-Lung and Triple-Negative Breast Cancers
Lead sponsor
Light Chain Bioscience - Novimmune SA
Phase
Phase 1
Overall status
Recruiting
Start date
April 29, 2022
Completion date
September 30, 2026
Enrollment
70 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

endometrioid ovarian cancer, epithelial ovarian cancer, non-squamous non-small-cell lung cancer, pancreatic adenocarcinoma (ductal adenocarcinoma), triple negative breast cancer